- Home
- ABOS vs INBX Comparison
ABOS vs INBX Comparison
Compare ABOS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- INBX
- Stock Information
- Founded
- ABOS 1996
- INBX 2010
- Country
- ABOS United States
- INBX United States
- Employees
- ABOS N/A
- INBX N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- INBX Health Care
- Exchange
- ABOS Nasdaq
- INBX Nasdaq
- Market Cap
- ABOS 109.6M
- INBX 430.2M
- IPO Year
- ABOS 2021
- INBX 2020
- Fundamental
- Price
- ABOS $1.53
- INBX $80.22
- Analyst Decision
- ABOS Strong Buy
- INBX Hold
- Analyst Count
- ABOS 3
- INBX 2
- Target Price
- ABOS $7.67
- INBX N/A
- AVG Volume (30 Days)
- ABOS 229.4K
- INBX 731.6K
- Earning Date
- ABOS 11-12-2025
- INBX 11-14-2025
- Dividend Yield
- ABOS N/A
- INBX N/A
- EPS Growth
- ABOS N/A
- INBX N/A
- EPS
- ABOS N/A
- INBX N/A
- Revenue
- ABOS N/A
- INBX $1,400,000.00
- Revenue This Year
- ABOS N/A
- INBX $563.00
- Revenue Next Year
- ABOS N/A
- INBX $230.77
- P/E Ratio
- ABOS N/A
- INBX N/A
- Revenue Growth
- ABOS N/A
- INBX N/A
- 52 Week Low
- ABOS $0.86
- INBX $10.81
- 52 Week High
- ABOS $2.47
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- ABOS 36.97
- INBX 67.67
- Support Level
- ABOS $1.51
- INBX $76.01
- Resistance Level
- ABOS $2.04
- INBX $84.07
- Average True Range (ATR)
- ABOS 0.16
- INBX 6.85
- MACD
- ABOS -0.07
- INBX -1.28
- Stochastic Oscillator
- ABOS 9.46
- INBX 56.51
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.